Research programme: VEGF gene therapy - Ark Therapeutics

Drug Profile

Research programme: VEGF gene therapy - Ark Therapeutics

Alternative Names: Ad VEGF-D variants; EG013

Latest Information Update: 23 Nov 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ark Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Fetal growth retardation

Most Recent Events

  • 08 Nov 2012 Discontinued - Preclinical for Fetal growth retardation in Finland (Intra-arterial)
  • 16 Mar 2011 Preclinical development is ongoing in Finland
  • 30 Nov 2010 Pharmacodynamics data from preclinical studies in Fetal growth retardation released by Ark Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top